CN1733183A - 治疗骨折的外用药物 - Google Patents
治疗骨折的外用药物 Download PDFInfo
- Publication number
- CN1733183A CN1733183A CNA2005100445063A CN200510044506A CN1733183A CN 1733183 A CN1733183 A CN 1733183A CN A2005100445063 A CNA2005100445063 A CN A2005100445063A CN 200510044506 A CN200510044506 A CN 200510044506A CN 1733183 A CN1733183 A CN 1733183A
- Authority
- CN
- China
- Prior art keywords
- radix
- fracture
- blood
- grams
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010392 Bone Fractures Diseases 0.000 title abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 34
- 244000235603 Acacia catechu Species 0.000 claims abstract description 8
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 11
- 239000009286 sanguis draxonis Substances 0.000 claims description 10
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 8
- 235000006226 Areca catechu Nutrition 0.000 claims description 8
- 241001489978 Eupolyphaga Species 0.000 claims description 8
- 241001057584 Myrrha Species 0.000 claims description 8
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052802 copper Inorganic materials 0.000 abstract description 4
- 239000010949 copper Substances 0.000 abstract description 4
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 235000006020 Acacia catechu Nutrition 0.000 abstract 1
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241001671653 Aconitum carmichaelii Species 0.000 abstract 1
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000489492 Arisaema Species 0.000 abstract 1
- 241001647745 Banksia Species 0.000 abstract 1
- 241000131329 Carabidae Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000241550 Cyathula Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 241001116742 Drynaria Species 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000501743 Gentiana macrophylla Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 description 48
- 239000008280 blood Substances 0.000 description 45
- 210000004369 blood Anatomy 0.000 description 42
- 208000002193 Pain Diseases 0.000 description 38
- 230000036407 pain Effects 0.000 description 37
- 210000000988 bone and bone Anatomy 0.000 description 34
- 230000001737 promoting effect Effects 0.000 description 26
- 210000003205 muscle Anatomy 0.000 description 20
- 230000006378 damage Effects 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 210000002435 tendon Anatomy 0.000 description 10
- 230000035876 healing Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 230000004087 circulation Effects 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 206010020649 Hyperkeratosis Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 208000003044 Closed Fractures Diseases 0.000 description 3
- 208000021945 Tendon injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- UCZJPQIEFFTIEV-UHFFFAOYSA-N 5-methoxy-6-methyl-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=C(C)C(=O)C=C2OC=1C1=CC=CC=C1 UCZJPQIEFFTIEV-UHFFFAOYSA-N 0.000 description 2
- KFJQLAOTTSPBMT-UHFFFAOYSA-N 6-methyl-3,4-dihydropyrano[3,4-c]pyridin-1-one Chemical compound C1COC(=O)C2=C1C=C(C)N=C2 KFJQLAOTTSPBMT-UHFFFAOYSA-N 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- FWKBXSPDFCAHFN-UHFFFAOYSA-N Dracorubin Natural products C1CC=2C(OC)=CC=3OC(C=45)=C(C)C(=O)C=C5OC(C=5C=CC=CC=5)=CC=4C=3C=2OC1C1=CC=CC=C1 FWKBXSPDFCAHFN-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940039750 aconitine Drugs 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- -1 demethyl dracorubin Chemical compound 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- DFNZYFAJQPLJFI-UHFFFAOYSA-N gentianine Chemical compound O=C1OCCC2=C1C=NC=C2C=C DFNZYFAJQPLJFI-UHFFFAOYSA-N 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- XUHJBXVYNBQQBD-UHFFFAOYSA-N mesaconitine Natural products COC1CC(O)C2(COC)CN(C)C3C(C(C45)(OC(C)=O)C(O)C6OC)C(OC)C2C31C4CC6(O)C5OC(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-UHFFFAOYSA-N 0.000 description 2
- XUHJBXVYNBQQBD-GQPWXMLZSA-N molport-002-525-145 Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H]6[C@@H](OC)[C@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H]4N(C)C[C@@]6([C@@H](C[C@@H]5OC)O)COC)C(=O)C1=CC=CC=C1 XUHJBXVYNBQQBD-GQPWXMLZSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000008130 triterpenoid saponins Chemical class 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JQNVCUBPURTQPQ-UHFFFAOYSA-N (25R)-Inokosterone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(CO)C)CCC33O)C)C3=CC(=O)C21 JQNVCUBPURTQPQ-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 1
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- JQNVCUBPURTQPQ-FTWMDKANSA-N Inokosterone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CC[C@H](CO)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 JQNVCUBPURTQPQ-FTWMDKANSA-N 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 229920000473 Phlobaphene Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VLZYGCGUSDGSGB-UHFFFAOYSA-N Stigmast-4,22-dien-3,6-dione Natural products CC(C)C1CCC2C1(C)CCC3(C)C4CCC5C(C)(CCCC5(C)C4=CCC23C)C(=O)O VLZYGCGUSDGSGB-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 229960003513 batilol Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 125000002871 cinnamic aldehydes group Chemical group 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- FWKBXSPDFCAHFN-DEOSSOPVSA-N dracorubin Chemical compound C1([C@H]2OC=3C=4C=5C=C(OC6=CC(=O)C(C)=C(C=56)OC=4C=C(C=3CC2)OC)C=2C=CC=CC=2)=CC=CC=C1 FWKBXSPDFCAHFN-DEOSSOPVSA-N 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229940095991 ferrous disulfide Drugs 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JQNVCUBPURTQPQ-XDWLXSIGSA-N inokosterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(CO)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 JQNVCUBPURTQPQ-XDWLXSIGSA-N 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- XMFOQHDPRMAJNU-UHFFFAOYSA-N lead(ii,iv) oxide Chemical compound O1[Pb]O[Pb]11O[Pb]O1 XMFOQHDPRMAJNU-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 210000000450 navicular bone Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明为治疗骨折的药物,属于中药领域,由当归、没药、川芎、川牛膝、血竭、生南星、土元、自然铜、肉桂、川乌、草乌、秦艽、孩儿茶、冰片、木香、骨碎补、川续断、鹿茸、麝香、铅丹、狗骨和香油按一定重量配比而成,结合中医“内病外治”的理论,采用经皮渗入内吸收方法的原理使药物迅速对骨折病变部位产生作用,具有活血祛瘀、行气通络、消肿止痛、舒筋活络、接骨续筋之功效。适用于肢体各个部位的闭合性骨折的治疗,治愈率高。
Description
技术领域
本发明属于中药领域,是一种治疗骨折的中药制剂。
背景技术
骨折是由于外力的作用破坏了骨的完整性或连续性,根据骨折处是否与外界相通分闭合性骨折和开放性骨折。祖国医学认为骨折的发生主要为外来暴力所致,骨折筋伤者,肢体伤于外,而气血损于内,瘀血停滞,气血不畅,肿胀疼痛,经络受阻,不通则痛。肢体各个部位均有可能遭受外力的伤害而造成一定的损伤,骨折是损伤性疾病中比较严重的病症,它可由生活损伤、交通损伤、农业损伤、运动损伤、灾害损伤、战争损伤等因素造成。
目前治疗骨折一般采用手法复位后用夹板或石膏外固定,手法复位不能达到解剖复位或功能复位时,以致影响骨折愈合和功能恢复,可行手术切开复位(铜板、螺丝钉、髓内针等)内固定。根据中医治疗骨折“局部与整体并重,外用与内服兼顾”的原则,主张给予必要的内外用药,临床应用中药治疗骨折,一般按初、中、后三期辩证用药。初期以“消”为主,多用散瘀止痛,行气通络的药物。中期以“和”为主,多用舒筋活络,接骨续筋的药物。后期以“补”为主,多用养气血,补肝肾兼温通经络的药物。
从中医观点分析,血不活则瘀不能去,瘀不去则骨不能接也。伤骨能及筋,伤筋亦能动骨,同时筋骨的损伤必然累及气血,气血两者互为依存,气病可以影响及血,血病亦可影响及气,以致气血同病,即伤后情志不舒,气血瘀滞而不通。故一系列症状除之发生,损伤日久,正气方耗,累及肝肾,则造成肝血肾精不充,筋骨是肝肾的外合,故伤筋损骨可累及肝肾精气,骨折后如肾生养精髓不足,则无以养骨,筋骨相连,骨折亦必伤筋,筋伤内动于肝,肝血不充,血无以养筋,故可影响筋骨的修复。传统中医药多以新伤续筋汤,接骨丹等方剂煎服,因服药时间长,服用不方便,有效成分不易煎出,且难以到达患处,故疗效皆不理想。
发明内容
本发明是这样实现的:
治疗骨折的药物,其特征在于是由下述重量配比的组份制作而成:当归72-95、没药74-95、川芎60-80、川牛膝45-90、血竭30-50、生南星50-80、土元70-95、自然铜70-98、肉桂32-50、川乌50-80、草乌24-35、秦艽30-55、孩儿茶24-45、冰片1 5-30、木香50-80、骨碎补50-90、川续断65-95、鹿茸2.4-4、麝香6-15、铅丹2200-2500、狗骨130-240、香油5000。
中医学强调整体观念,对于骨折的病因、病机、辩证论治合理组方有着独特的理论和宝贵经验。方中纯中药组合,符合并按照中国药典及药理配伍,是传统医学与现代科学的结晶。组方中的药材,经多次泡制,提纯,精炼,使其药物的渗透性更为良好,充分加大了人体对药物的吸收,其疗效更为快捷。结合中医“内病外治”的理论,采用经皮渗入内吸收祛瘀生新原理使药物迅速对骨折病变部位产生作用,具有活血祛瘀行气通络,清肿止痛,舒筋活络,接骨续筋之功效。
本发明具有如下临床效果:
1、药物通过人体毛孔进入微循环,快速渗入病理局部激活早期凝血机制,同时也激活纤维蛋白溶解过程。
2、祛瘀血肿胀:本发明药物对骨折有明显的祛瘀,消肿作用,使用初期瘀血肿胀皆有不同程度减轻,可有效治疗骨折。
3、行气止痛快:对于骨折20分钟即产生明显止痛效果,连续使用可使气血、经络通畅。
4、接骨续筋疗效快,对于各个部位的骨折,10天即有骨痂生成,平均临床愈合时间为36天。
5、适用范围广:适用于躯干骨及四肢骨骨折的治疗。
6、治愈率高:本发明对骨折的有效率达100%,治愈率达91.5%。
现代药理研究表明:
当归:补血、活血止痛。含挥发油0.2-0.4%,其中主要为藁本内酯及正丁烯酜内酯。另含脂肪油、叶酸、生物素、维生素A类物质、维生素B12、维生素E等。临床用于跌打损伤、瘀血作痛、痹痛麻木,经络不利等。
没药:活血止痛、消肿生肌。主要成份为树脂、树皮和挥发油,临床用于跌打损伤、寒湿痹痛等。
川芎:活血行气、祛风止痛。含挥发油、生物碱、酸类物质、中性物质、有机酸等,川芎注射液骨折断端注射,能加速血肿吸收,机化并能促进骨病形成。
川牛膝:活血祛瘀,引血下行,强筋骨,利关节,含促脱皮甾酮、牛膝甾酮、三萜皂甙。临床用于跌打伤痛等症。
血竭:内服活血止痛,外用止血生肌敛疮。含血竭素、去甲基血竭等、血竭红素、去甲基血竭红素以及几种黄烷醇、查耳酮、树脂酸等。能降低红细胞压积,增加红细胞及血小板电泳速度,抑制血小板聚集。
生南星:搜风祛痰,燥湿通络。含三萜皂甙、安息香酸、淀粉、氨基酸、a一甘露醇等。外敷能消肿止痛。
土元:破血逐瘀,续筋接骨。主要含生物碱、B-谷甾醇、鲨肝醇、尿嘧啶、尿囊素等化合物。临床用于骨折损伤、瘀滞疼痛等。
自然铜:散瘀止痛,接骨疗伤。含二硫化铁、镍、砷、锑、铜、铁等,临床用于跌打骨折瘀阻肿痛等。
肉桂:温肾壮阳、温中祛寒,温经止痛。含挥发油1-2%,其中主要成份为桂皮醛及桂皮酚。有一定升高白细胞及抗放射作用。
川乌:祛风散寒止痛。含乌头碱、中乌头碱、次乌头碱等。小鼠注射乌头注射液5mg/kg,20min痛阈提高2.4倍,60min后提高3倍。临床用于寒湿痹痛、跌打伤痛等。
草乌:祛风散寒止痛。含乌头碱、中乌头碱、次乌头碱等。临床用于寒湿痹痛,跌打伤痛等。
秦艽:祛风解热,活血止痛。含龙胆碱、龙胆次碱、龙胆碱丙、龙胆苦甙、糖及挥发油。临床用于祛风湿、疗痹痛等。
冰片:开窍醒神、清热止痈。含右旋龙脑、消旋龙脑、左旋龙脑。
孩儿茶:收湿敛疮,生肌止血。启儿茶鞣酸、赭朴鞣质,以及非瑟素、槲皮素等。用于一切诸疮,生肌定痛、止血,多作外用。
木香:行气、调中、止痛。含挥发油、木香碱等。有解除平滑肌痉挛作用。
骨碎补:补肾,活血、止血。含柚皮甙、双氢黄酮甙、骨碎补酸等。骨碎补有一定改善软骨细胞功能,推迟细胞退行性变的作用,促进骨对钙的吸收,并提高血钙和血磷的水平,有利于骨折的愈合。临床用于跌打闪挫或金疮,损伤筋骨。
川续断:实肝肾、行血脉、续筋骨。含生物碱、挥发油、维生素E、蔗糖、胡萝卜甙和有色物质。临床用于腰膝骨痛,跌打损伤等。
鹿茸:补肾阳,益精血,强筋骨。含25种氨基酸,以脯氨酸、赖氨酸、丙氨酸为最多,又含雌激素、雄激素、前列腺素及26种微量元素,其中铜、铁、锌、锰、铬、钼、镍、钴8种为人体必须元素。有性激素作用,能加速骨折伤口的愈合。
麝香:开窍醒神,活血散结,止痛、催产。含麝香酮、麝香呲啶、胆甾醇、水溶性多肽、脂肪酸,氨化合物(碳酸钙、尿素、氨基酸)和无机盐。本品辛散温通,芳香走窜,能入十二经,散瘀之力颇强,为血瘀诸痛之良药。
铅丹:外用解毒止痒,收敛生肌,内服截疟,又为膏药原料。主要含四氧化三铅,煎膏用止痛生肌。
狗骨:祛风定痛,强筋健骨。含脂肪、骨胶原、无机物(磷酸钙、碳酸钙、碳酸镁)。主要用于:风湿痹痈,四肢拘挛,关节不利,筋骨痿弱等。
配方中以活血祛瘀,行气通络,消肿止痛,舒筋活络,接骨续筋为原理,加快骨折愈合为出发点。跌打损伤、筋断骨折为痛为肿,首当活血、祛瘀、祛痛为主,方中以当归、没药、川牛膝、川芎、血竭、生南星祛瘀、活血、止痛、生肌。辅以土元、自然铜逐瘀、散瘀、疗伤接骨,并以性味辛热之肉桂,川乌、草乌、散寒止痛,温通经脉,秦艽、孩儿茶、冰片清热止痛、祛风湿助血竭以止血、生肌,配以木香行气和营,木香乃三焦气分之药,能升降诸气。按照中医“肝主筋”、“肾主骨”的理论,补肝肾能起到强壮筋骨的作用,故以狗骨、骨碎补、川续断、鹿茸滋补肝肾,接骨续筋,强健筋骨,并配伍气味辛香,走窜通络之麝香,助诸活血祛瘀药以散结,开经络之壅滞以止痛,铅丹解毒止痒,收敛生肌,又为制作膏药的原料。各药合用,使瘀去新生,气行络通则骨接也。
具体实施方式
下面结合实施例对本发明作详细说明。
实施例1:取当归80克、没药80克、川芎70克、川牛膝60克、血竭40克、生南星65克、土元80克、自然铜80克、肉桂45克、川乌60克、草乌30克、秦艽40克、孩儿茶30克、冰片20克、木香60克、骨碎补60克、川续断80克、鹿茸3克、麝香12克、铅丹2500克、狗骨180克、香油5000克。将麝香、没药、冰片、血竭、儿茶、自然铜、鹿茸研为细末密封备用。再将当归、川芎、川牛膝、生南星、土元、肉桂、川乌、草乌、秦艽、木香、骨碎补、川续断、狗骨,放入香油锅内浸泡二天,用文火煎至药呈焦黄色,用纱布过滤去渣,油煎至滴水成珠不散为度,入铅丹不停搅拌,锅内烟雾弥漫,速将油锅离火,待油的温度降至60℃左右时,将研为细末备用的药物入锅内,继续搅拌至药油完全冷却凝固,即成药膏,用时将药膏摊于较密的布上,每贴60g,使用时每周1贴,贴于骨折患处,可有效治疗肢体各个部位的闭合性骨折。
实施例2:取当归85克、没药90克、川芎75克、川牛膝65克、血竭40克、生南星60克、土元85克、自然铜85克、肉桂50克、川乌60克、草乌30克、秦艽45克、孩儿茶35克、冰片25克、木香55克、骨碎补70克、川续断85克、鹿茸5克、麝香6克、铅丹2500克、狗骨150克、香油5000克。制法及使用方法同
实施例1。
对比实验
为验证本发明药物,于2000年-2004年在阳谷县人民医院进行如下临床试验:
一、基本情况
1、分组
选择在常规整复、固定的基础上闭合性骨折67例,随机分为二组,一组47例为治疗组,另一组20例为对照组。
2、性别、年龄
治疗组男性32例,女性15例,对照组男性13例,女性7例。治疗组年龄在10岁以下4例,10-19岁10例,20-39岁15例,40-59岁11例,60岁以上7例,平均年龄39岁。对照组年龄在10岁以下2例,10-19岁5例,20-39岁7例,40-59岁3例,60岁以上3例,平均年龄40岁。
3、骨折的分类
治疗组克雷氏骨折16例,尺桡骨中段骨折21例、肋骨骨折10例,参照组克雷氏骨折6例,尺桡骨中段骨折8例,肋骨骨折6例。
二、治疗方案
治疗组采用本发明外用制剂加骨科常规护理治疗,每周1贴,一共治疗4周为一疗程,对照组采用新伤续筋汤,接骨丹等方剂加骨科常规护理治疗4周为一疗程。
三、疗效标准
1、痊愈:具备临床愈合标准的条件,X线摄片显示骨小梁通过骨折线为痊愈。
2、有效:伤后症状减轻,骨折愈合时间较临床愈合时间短,无骨不愈合者为有效。
3、无效:症状减轻不明显,X线摄片骨折线处无骨痂生成,不愈合者为无效。
四、治疗结果
1、治疗组痊愈43例,有效4例,无效0例。对照组痊愈11例,有效8例,无效1例。
| 克雷氏骨折人数 | 尺桡骨中段骨折人数 | 肋骨骨折人数 | 合计 | |
| 治疗组 | 16 | 21 | 10 | 47 |
| 对照组 | 6 | 8 | 6 | 20 |
表一:治疗前
| 痊愈 | 有效 | 无效 | ||||
| 病例数 | 比例 | 病例数 | 比例 | 病例数 | 比例 | |
| 治疗组 | 43 | 91.5% | 4 | 8.5% | 0 | 0 |
| 对照组 | 11 | 55% | 8 | 40% | 1 | 5% |
表二:治疗后
五、不良反应
无毒副作用。
六、注意事项
1、本品为外用药,禁止内服。
2、皮肤破溃,感染者禁用。
七、结论:
与对照组相比结果骨折的痊愈比例大大提高为91.5%,总有效率达100%,明显高于对照组其他药物治疗的95%,治疗组的无效率为0,低于对照组的5%。证明本发明药物对骨折有提前愈合的作用。
八、具体病例:
病例1:马某,男,21岁,未婚,于2003年5月27日被汽车撞伤左足部,伤后,肿胀疼痛,不能站立。查体:表情痛苦,面色苍白,左足关节肿胀青紫,压痛明显,触伤可闻及骨擦音异常活动存在,踝关节活动功能受限。在阳谷县人民医院X线摄片示:左足舟状骨前侧可见明显横形骨折线。诊断足舟状骨骨折。在采用手法复位后加用本发明药物外敷加用石膏外固定。治疗8天肿胀基本消失,治疗12天经X线摄片示骨折线处有骨痂生成。治疗28天经X线摄片示,骨折线模糊,有连续性骨痂通过骨折线,3个月后随访复查,骨折解剖对位,骨性愈合,无后遗症。
病例2:张某,女,40岁,于2003年4月17日被他人骑自行车撞倒,右手着地,伤后腕部肿胀疼痛,不能活动。查体:右腕关节肿胀,明显压痛,呈“餐叉样”畸形,触诊有骨擦音,异常活动,关节功能受限。在阳谷县人民医院X线摄片示:桡骨头上骨皮质,骨小梁连续性横形断裂,略有移位。诊断:克雷氏骨折。在采用手法复位后加用本发明药物外敷治疗,克雷夹板外固定。治疗7天肿胀基本消失,治疗10天经X线摄片示:骨折线处有骨痂生成,治疗29天经X线摄片显示,骨折线模糊有连续性骨痂通过骨折线。经检查局部无压痛,无异常活动。在解除外固定的情况下,上肢能平举1kg重物超过1分钟,以上显示表明骨折已达临床愈合。治疗38天经X线摄片显示:骨小梁通过骨折线。表明患者骨折已达到骨性愈合标准。2003年7月28日随访,复查,解剖对位,骨性愈合,无后遗症。
Claims (2)
1、治疗骨折的药物,其特征在于由下述重量配比的组份制作而成:当归72-95、没药74-95、川芎60-80、川牛膝45-90、血竭30-50、生南星50-80、土元70-95、自然铜70-98、肉桂32-50、川乌50-80、草乌24-35、秦艽30-55、孩儿茶24-45、冰片15-30、木香50-80、骨碎补50-90、川续断65-95、鹿茸2.4-4、麝香6-15、铅丹2200-2500、狗骨130-240香油5000。
2、根据权利要求1所述的治疗骨折的药物,其特征在于上述组份的重量配比为:当归80、没药80、川芎70、川牛膝60、血竭40、生南星65、土元80、自然铜80、肉桂45、川乌60、草乌30、秦艽40、孩儿茶30、冰片20、木香60、骨碎补60、川续断80、鹿茸3、麝香12、铅丹2500、狗骨180、香油5000。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100445063A CN100446796C (zh) | 2005-08-25 | 2005-08-25 | 治疗骨折的外用药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100445063A CN100446796C (zh) | 2005-08-25 | 2005-08-25 | 治疗骨折的外用药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733183A true CN1733183A (zh) | 2006-02-15 |
| CN100446796C CN100446796C (zh) | 2008-12-31 |
Family
ID=36075938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100445063A Expired - Fee Related CN100446796C (zh) | 2005-08-25 | 2005-08-25 | 治疗骨折的外用药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100446796C (zh) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102309646A (zh) * | 2011-10-14 | 2012-01-11 | 山东方健制药有限公司 | 治疗骨折的药物及制备使用方法 |
| CN102824560A (zh) * | 2012-08-27 | 2012-12-19 | 靳先玲 | 一种治疗心虚胆怯型闭合性骨折的中药洗剂制备方法 |
| CN103908655A (zh) * | 2014-05-03 | 2014-07-09 | 赵东顺 | 一种治疗手折裂及手腕断的外敷散剂 |
| CN104474192A (zh) * | 2014-12-25 | 2015-04-01 | 平阴县中医医院 | 一种治疗骨折及急性软组织损伤的药物及其制备方法 |
| CN104491819A (zh) * | 2015-01-05 | 2015-04-08 | 李旭振 | 一种治疗骨折、肌腱损伤的中药膏药及其制备方法 |
| CN104524525A (zh) * | 2015-01-05 | 2015-04-22 | 李旭振 | 一种治疗风湿、关节炎、骨性病变的膏药及其制备方法 |
| CN104587349A (zh) * | 2015-02-13 | 2015-05-06 | 袁艳荣 | 一种治疗四肢骨折的药物组合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1217935A (zh) * | 1998-10-28 | 1999-06-02 | 刘方明 | 一种治疗伤筋断骨的药膏及制备方法 |
| CN1218729C (zh) * | 2003-02-21 | 2005-09-14 | 付宝 | 血茸骨愈膏及其制备方法 |
-
2005
- 2005-08-25 CN CNB2005100445063A patent/CN100446796C/zh not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102309646A (zh) * | 2011-10-14 | 2012-01-11 | 山东方健制药有限公司 | 治疗骨折的药物及制备使用方法 |
| CN102309646B (zh) * | 2011-10-14 | 2013-03-20 | 山东方健制药有限公司 | 治疗骨折的药物及制备使用方法 |
| CN102824560A (zh) * | 2012-08-27 | 2012-12-19 | 靳先玲 | 一种治疗心虚胆怯型闭合性骨折的中药洗剂制备方法 |
| CN103908655A (zh) * | 2014-05-03 | 2014-07-09 | 赵东顺 | 一种治疗手折裂及手腕断的外敷散剂 |
| CN104474192A (zh) * | 2014-12-25 | 2015-04-01 | 平阴县中医医院 | 一种治疗骨折及急性软组织损伤的药物及其制备方法 |
| CN104491819A (zh) * | 2015-01-05 | 2015-04-08 | 李旭振 | 一种治疗骨折、肌腱损伤的中药膏药及其制备方法 |
| CN104524525A (zh) * | 2015-01-05 | 2015-04-22 | 李旭振 | 一种治疗风湿、关节炎、骨性病变的膏药及其制备方法 |
| CN104587349A (zh) * | 2015-02-13 | 2015-05-06 | 袁艳荣 | 一种治疗四肢骨折的药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100446796C (zh) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091202B (zh) | 一种治疗骨折的中药组合物及其制备方法 | |
| CN102988657A (zh) | 一种治疗骨折及跌打损伤的膏药及其制备方法 | |
| CN101361872A (zh) | 一种快速治疗骨折及术后骨不连、愈合迟缓的中药 | |
| CN102895460B (zh) | 一种用于骨折、软组织损伤的中药组合物 | |
| CN100446796C (zh) | 治疗骨折的外用药物 | |
| CN103142938A (zh) | 一种治疗跌打损伤骨折的膏药 | |
| CN103520633B (zh) | 抗癌活血消痞膏的加工方法 | |
| CN102861196B (zh) | 一种接骨中药 | |
| CN102600256A (zh) | 一种用于跌打损伤中药组合物 | |
| CN1284580C (zh) | 一种治疗股骨头坏死的胶囊 | |
| CN103127349B (zh) | 一种治疗跌打损伤的药物 | |
| CN103585483B (zh) | 一种治疗膝骨性关节病的中药组合物及其制备方法 | |
| CN102846738A (zh) | 风湿跌打骨痛膏 | |
| CN102552610B (zh) | 一种治疗骨折的中药组合物 | |
| CN101195002B (zh) | 祛痛保健中药贴膏 | |
| CN101011448A (zh) | 治疗股骨头无菌性坏死的中药胶囊 | |
| CN104524471A (zh) | 一种消肿止痛膏 | |
| CN1876122A (zh) | 治疗骨质增生、风寒湿痹、劳损、扭伤的药膏及制作方法 | |
| CN105770251A (zh) | 一种治疗颈椎病、腰椎病和关节炎的通宁胶囊 | |
| CN109966451A (zh) | 一种正骨止痛的中药组合物 | |
| CN109010549A (zh) | 接骨祛风活血止痛膏及其制备方法 | |
| CN102908535B (zh) | 一种治疗腰腿痛药酒 | |
| CN101439165B (zh) | 一种治疗骨伤的膏药及其制备方法 | |
| CN106421098B (zh) | 治疗多种骨病的外用中药组合物 | |
| CN105560427A (zh) | 一种透皮通关散 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081231 Termination date: 20090925 |